In summary, our findings suggest that the combination of the MEK inhibitor trametinib and the RTK inhibitor anlotinib has high antitumor efficacy for KRAS-mutant NSCLC, with the underlying molecular mechanism involving the MEK/RTK-IGFBP2-RTK signaling loop. Here, IGFBP2 is linked to non-small cell lung carcinoma.